Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran
- 31 July 2007
- journal article
- research article
- Published by Elsevier BV in Acta Tropica
- Vol. 103 (1), 33-40
- https://doi.org/10.1016/j.actatropica.2007.05.005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Development of miltefosine as an oral treatment for leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica ParasitesPLoS Medicine, 2006
- Miltefosine to treat leishmaniasisExpert Opinion on Pharmacotherapy, 2005
- Miltefosine for New World Cutaneous LeishmaniasisClinical Infectious Diseases, 2004
- Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasisInternational Journal of Dermatology, 2004
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral AgentClinical Infectious Diseases, 2001
- Short‐Course of Oral Miltefosine for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 2000
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Oral treatment of visceral leishmaniasis with miltefosinePathogens and Global Health, 1999